Results 141 to 150 of about 39,435 (300)

Diabetes en la era de la inteligencia artificial

open access: yesRevista de la Sociedad Argentina de Diabetes
Vamos a intentar responder a esta consigna: ¿cómo la inteligencia artificial (IA) y la tecnología están revolucionando nuestro campo de trabajo y transformando la vida de nuestros pacientes?
Alejandro Dain
doaj   +1 more source

Meeting Report: The Fourth Artificial Pancreas Workshop: Testing and Adoption of Current and Emerging Technologies

open access: yes, 2017
On July 6 and 7, 2016 the Fourth Artificial Pancreas Workshop: Testing and Adoption of Current and Emerging Technologies was held on the National Institutes of Health (NIH) Campus at the Lister Hill Auditorium.
David C. Klonoff   +2 more
core   +1 more source

A multilevel perspective on MSH6‐associated Lynch syndrome: Integrating molecular, biological, and clinical insights

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome, caused by a germline pathogenic variant in one of the mismatch repair (MMR) genes. Among these, MSH6‐associated LS represents a distinct subtype with unique molecular and clinical characteristics.
Salwa Ben Yahia   +4 more
wiley   +1 more source

Event-triggered smart dual hormone artificial pancreas for patient-specific drug delivery

open access: yesScientific Reports
Diabetes is a chronic disorder that disrupts the body’s ability to regulate blood glucose (BG) levels, leading to dangerous fluctuations such as hypoglycemia and hyperglycemia. In managing Type 1 Diabetes (T1D), the Dual Hormone Artificial Pancreas (DHAP)
Divya Govindaraju, Sutha Subbian
doaj   +1 more source

Pancreatic Cancer Early Detection Biomarkers for High‐Risk Individuals: Insights From the PRECEDE Consortium

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers due to its asymptomatic progression, late‐stage diagnosis, and treatment resistance. Efforts in early detection have centered on identifying imaging features and liquid biopsy biomarkers capable of detecting PDAC and its high‐grade precursors before clinical symptoms ...
Christine Worthington   +105 more
wiley   +1 more source

The Artificial Pancreas: Current Algorithms and Homeostasis

open access: yes, 2020
Diabetes type 1 is a homeostatic imbalance caused by lack of insulin producing beta-cells in the pancreas. Standard treatment is very invasive, time-consuming, and error prone.
Koelewijn, M. W. H. M.
core  

Engineering Bacteria for Medicine: Delivery, Diagnosis, and Therapy

open access: yesiMetaMed, EarlyView.
ABSTRACT With rapid advances in synthetic biology and genetic engineering, genetically engineered bacteria (GEB) have emerged as a promising platform for biological therapy, addressing key limitations of conventional drug delivery systems and demonstrating significant clinical potential.
Shiyu Xia   +11 more
wiley   +1 more source

Emerging Human‐Based Research Technologies for Investigating the Pathomechanisms and Therapies for Vascular Diseases

open access: yesiNew Medicine, EarlyView.
ABSTRACT It is estimated that a large proportion of drug candidates fail in human clinical trials, mainly because animal models cannot fully replicate human disease and because of differential responses to various medications between humans and animals.
Weiping Ding, Iqra Ilyas, Suowen Xu
wiley   +1 more source

Artificial Pancreas

open access: yesJinko Zoki, 1980
OOKURA, K.   +6 more
  +6 more sources

Implantable drug delivery system: Frontiers of medicine‐engineering interdisciplinary

open access: yesInterdisciplinary Medicine, EarlyView.
This review systematically summarizes the driving mechanisms of implantable on‐demand drug delivery systems (IDDS), including endogenous, exogenous, and closed‐loop strategies. It highlights the pivotal roles of flexible electronics and miniaturization in enhancing the tissue conformity and spatial adaptability.
Yu Zeng   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy